Advertisement

Search Results

Advertisement



Your search for The ,The matches 34676 pages

Showing 34051 - 34100


solid tumors
bladder cancer

Patients With Poor Nutritional Status Before Radical Cystectomy Have a Higher Risk of Postoperative Complications

Patients with bladder cancer are two times more likely to have complications after a radical cystectomy procedure if they have a biomarker for poor nutritional status before the operation, according to study findings presented at the 2013 Clinical Congress of the American College of Surgeons....

cns cancers

Researchers Identify Potential New Drug for Inherited Cancer

Scientists from The Scripps Research Institute have identified a new drug candidate for an inherited form of cancer with no known cure. The new study showed the drug candidate—known as FRAX97—slowed the proliferation and progression of tumor cells in animal models of neurofibromatosis...

breast cancer

ACOSOG Z1071 Trial Does Not Support Sentinel Lymph Node Surgery Following Neoadjuvant Chemotherapy for Node-Positive cN1 Breast Cancer

Sentinel lymph node surgery provides reliable nodal staging information and is associated with less morbidity than axillary lymph node dissection in patients with clinically node-negative breast cancer. The American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) trial examined the...

lung cancer
issues in oncology

Study Identifies Prognostic DNA Methylation Signature for Stage I NSCLC

There is an absence of biomarkers to indicate which patients with stage I non–small cell lung cancer (NSCLC) would best benefit from adjuvant chemotherapy. In a study reported in the Journal of Clinical Oncology, Juan Sandoval, PhD, of the Bellvitge Biomedical Research Institute in...

solid tumors

Everolimus Does Not Improve Overall Survival in Previously Treated Advanced Gastric Cancer

In a phase III trial (GRANITE-1 study) reported in Journal of Clinical Oncology by Atsushi Ohtsu, MD, PhD, of the National Cancer Center Hospital East in Kashiwa, Japan, and colleagues, everolimus (Afinitor) plus best supportive care did not prolong overall survival compared with placebo plus best...

colorectal cancer
issues in oncology

PIK3CA Mutation Predictive of Relapse-Free Survival Benefit of Aspirin in Colorectal Cancer

Although nonsteroidal anti-inflammatory drugs such as aspirin have been shown to be protective against colorectal cancer and are associated with reduced disease recurrence and improved outcome, they are also associated with toxicities that limit their use in therapy. Recent data suggest that the...

leukemia

Better Leukemia-Free and Overall Survival in AML in First Remission With Cyclophosphamide Plus Busulfan vs Total-Body Irradiation

Myeloablative conditioning with cyclophosphamide combined with intravenous busulfan (Busulfex) was associated with better leukemia-free and overall survival than conditioning with cyclosphosphamide and total-body irradiation in patients with acute myeloid leukemia (AML) who were in first complete...

leukemia

Study Assesses Frequency of Allogeneic Hematopoietic Cell Transplantation in Patients With AML in First Complete Remission

In a study reported in Journal of Clinical Oncology, Raya Mawad, MD, of Fred Hutchinson Cancer Research Center, and colleagues assessed the frequency of allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) in first complete remission at their institution and...

breast cancer

Radiotherapy After Local Excision for DCIS Reduces Long-Term Risk of Local Recurrence

As reported in Journal of Clinical Oncology, Mila Donker, MD, of the Netherlands Cancer Institute, and colleagues analyzed the effects of adjuvant radiotherapy after local excision for ductal carcinoma in situ (DCIS) on long-term risk for local recurrence and survival in patients from the EORTC...

skin cancer

Patients With Melanoma Do Not Maintain Cautious Behavior About Limiting Exposure to UV Radiation From the Sun

Patients with cutaneous malignant melanoma “do not maintain the cautious sun behavior they exhibit just after … diagnosis,” even though they are at increased risk for developing a second primary melanoma, data from a Danish study suggested. Based on measurements...

breast cancer

ASCO and the College of American Pathologists Issue Updated Guideline on HER2 Testing in Breast Cancer

ASCO and the College of American Pathologists (CAP) today issued a joint, updated guideline to improve the accuracy and reporting of human epidermal growth factor receptor 2 (HER2) testing in patients with invasive breast cancer. The six-recommendation guideline is based on a systematic review of...

skin cancer
issues in oncology
survivorship

Intervention Program Improves Sun Protection Practices Among Children of Melanoma Survivors

Children of melanoma survivors were more likely to wear hats and reapply sunscreen after receiving a multimedia informational program designed specifically for them. These new findings were included in research published in Cancer Epidemiology, Biomarkers & Prevention. A team of researchers...

gynecologic cancers

Etirinotecan Pegol Shows Activity in Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer

Etirinotecan pegol is a topoisomerase-I inhibitor that prolongs systemic exposure to the active metabolite of irinotecan. In a phase II trial reported in Journal of Clinical Oncology, Ignace B. Vergote, MD, PhD, of University Hospital Leuven in Belgium, and colleagues found that the agent produced...

hepatobiliary cancer

Poorer Overall Survival With Sunitinib vs Sorafenib in Advanced Hepatocellular Cancer

In an open-label phase III superiority/noninferiority trial reported in Journal of Clinical Oncology by Ann-Lii Cheng, MD, of National Taiwan University Hospital in Taipei, sunitinib (Sutent) was associated with significantly poorer overall survival compared with sorafenib (Nexavar) in a population ...

health-care policy
survivorship

Older Cancer Survivors in Rural Areas Forgo Health Care Due to Cost

Rural cancer survivors aged 65 or older were 66% more likely to forgo routine follow-up health care and 54% more likely to forgo dental care because of cost, compared with their urban counterparts, according to a study by Nynikka Palmer, DrPH, MPH, Post-doctoral Fellow in the Department of Social...

solid tumors

Ramucirumab Prolongs Survival in Advanced Gastric Cancer

An investigational targeted drug that reduces blood flow to tumors prolonged the survival of patients with advanced stomach cancer after standard treatments failed, according to results of large multicenter clinical trial reported by Charles S. Fuchs, MD, MPH, of Dana-Farber Cancer Institute, and...

prostate cancer

Long-Term Follow-up Indicates Increased Telomere Length With Lifestyle Change in Men With Low-Risk Prostate Cancer

Short telomere length in peripheral blood mononuclear cells is associated with aging and such age-related diseases as cancer, stroke, vascular dementia, cardiovascular disease, obesity, osteoporosis, and diabetes. Telomere attrition is considered a potential mechanism in triggering the chromosomal...

leukemia

Flow Cytometric Residual Disease Highly Prognostic in Older AML Patients

Older patients with acute myeloid leukemia (AML) have a high relapse rate after standard chemotherapy. In a study reported in Journal of Clinical Oncology, Sylvie D. Freeman, MD, PhD, of University Hospitals Birmingham National Health Service Trust, and colleagues investigated whether assessing...

leukemia

Flow Cytometric Minimal Residual Disease Highly Prognostic in AML Patients Aged Under 60

In a study reported in Journal of Clinical Oncology, Monique Terwijn, PhD, of the VU University Medical Centre in Amsterdam, and colleagues assessed the prognostic performance of flow cytometric minimal residual disease detection in acute myeloid leukemia (AML) patients aged < 60 years. They...

breast cancer
issues in oncology

BRCA1 and BRCA2 Mutation Carriers Not at Greater Risk of Earlier Natural Menopause

Some data suggest that BRCA1 mutations are associated with occult primary ovarian insufficiency and that BRCA1 and BRCA2 mutation carriers have earlier natural menopause than noncarrier relatives. A study reported in Journal of Clinical Oncology by Ian M. Collins, MD, of Peter MacCallum Cancer...

breast cancer

Increased Physical Activity and Walking Reduces Breast Cancer Risk

A large epidemiology study of postmenopausal women by researchers at the American Cancer Society (ACS) has found that women who participated in at least 1 hour of vigorous physical activity every day had a 25% lower risk of breast cancer, and those who walked for at least 7 hours per week had a 14% ...

survivorship

Long-Term Survivors of Childhood Cancer Exhibit Vascular Endothelial Damage

In a study reported in Journal of Clinical Oncology, Cornelia A.J. Brouwer, of the University Medical Center Groningen in the Netherlands, and colleagues assessed vascular parameters in long-term childhood cancer survivors and sibling controls. They found that survivors who had received...

breast cancer

Lactation May Be Linked to Triple-Negative Breast Cancer in Mexican Women

Scientific data suggest that a woman reduces her risk of breast cancer by breastfeeding, having multiple children, and giving birth at a younger age. However, a study led by the University of California, San Diego School of Medicine, indicates that women of Mexican descent may not fit that profile. ...

lymphoma

Genetic Anti-Inflammatory Defect May Predispose Children to Lymphoma

New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma. Results of the study, published online today in Blood, reveal an important association between the genetic defect, which causes chronic intestinal...

Oral CMX001 100 mg Twice Weekly Reduces Cytomegalovirus Events in Patients Receiving Hematopoietic Cell Transplants

The anti-cytomegalovirus agent CMX001 is an oral lipid acyclic nucleoside phosphonate that is absorbed in the small intestine and transported throughout the body as a phospholipid. It is converted intracellularly to cidofovir diphosphate, but unlike cidofovir, is not a substrate of organic ion...

breast cancer

Breast Cancer Rates Are Rising Among African American Women

Although, historically, white women aged 40 years and older have had the highest incidence rates of breast cancer, the rising rate of breast cancer among African American women—especially among women aged 50 to 59—is narrowing the gap, according to a study by American Cancer Society...

lymphoma

Addition of Rituximab Does Not Improve Outcome in Aggressive B-Cell Lymphoma With Skeletal Involvement, but Radiotherapy Benefit Found

In a retrospective analysis of German High-Grade Non-Hodgkin Lymphoma Study Group trials reported in Journal of Clinical Oncology, Gerhard Held, MD, of Saarland University Medical School in Homburg, and colleagues assessed the impact of rituximab (Rituxan) and radiotherapy on outcome in patients...

ASCO Releases Statement on the Impact of the Government Shutdown on Cancer Care

All nonessential government services were suspended at midnight after Congress failed to reach a budget compromise to keep the government funded before the start of the new fiscal year beginning on October 1, 2013. ASCO issued a statement today in response to the government shutdown and will be...

prostate cancer
issues in oncology

ECC 2013: French Study Finds Routine PSA Screening Does More Harm Than Good

There is no consensus on the value of routine prostate-specific antigen (PSA) screening. Weighing in on this issue, investigators presented a study at the European Cancer Congress 2013 in Amsterdam (Abstract 1481) suggesting that population-based PSA screening does more harm than good. The...

Treatment With Losartan May Improve Delivery of Chemotherapy Drugs in Tumors

Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In a report published in Nature Communications, investigators from Massachusetts General Hospital (MGH) described how the angiotensin...

breast cancer

Long-Term Results of UK START Trials Support Hypofractionated Adjuvant Radiotherapy in Invasive Early Breast Cancer

The 5-year results of the UK Standardisation of Breast Radiotherapy (START) trials suggested that lower total doses of radiotherapy delivered in fewer, larger doses were at least as safe and effective as the historical standard regimen of 50 Gy in 25 fractions as adjuvant therapy for early breast...

breast cancer

ECC 2013: Strong Showing for Ado-Trastuzumab Emtansine in Heavily Pretreated Advanced HER2-Positive Breast Cancer

Results of the phase III TH3RESA trial show that the antibody-conjugate ado-trastuzumab (Kadcyla, previously known as T-DM1) extends progression-free survival in women with advanced HER2-positive breast cancer that progressed on two or more previous HER2-directed therapies including trastuzumab...

colorectal cancer

ECC 2013: TP53 Status Predicts Benefit From Neoadjuvant Cetuximab in Rectal Cancer

In a retrospective analysis of the randomized phase II EXPERT-C trial presented at the European Cancer Congress 2013 (Abstract LBA7), TP53 emerged as a strong, independent predictive biomarker for the benefit of cetuximab (Erbitux) in high-risk, locally advanced rectal cancer, according to...

breast cancer
issues in oncology

ECC 2013: PI3KCA-Mutant Tumors Not Likely to Respond to Neoadjuvant HER2 Blockade

In patients with early breast cancer receiving anti-HER2 therapy in the NeoALTTO trial, mutations in PIK3CA were associated with lower rates of pathologic complete response, Jose Baselga, MD, reported at the European Cancer Congress 2013 (Abstract 1859) in Amsterdam. In patients treated with the...

lung cancer

ECC 2013: Novel Anti-PD-L1 Antibody Achieves Durable Responses in Phase I Study of Patients With Metastatic NSCLC, Smokers Included

For the first time, an immunotherapy shows promise in smokers with non–small cell lung cancer (NSCLC). The engineered monoclonal antibody MPDL3280A achieved encouraging and durable responses in a phase I study in metastatic NSCLC in smokers and nonsmokers, and with squamous and adenocarcinoma ...

prostate cancer
survivorship

Men With Advanced Prostate Cancer Worry More About Burdening Family and Friends Than Dying, Survey Finds

Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...

breast cancer
gynecologic cancers
issues in oncology

ECC 2013: Continuous Combined Hormone Replacement Therapy Protects Against Endometrial Cancer

According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA13) by Rowan Chlebowski, MD,...

breast cancer

ECC 2013: Radiation to Chest Lymph Nodes Improves Survival in Early Breast Cancer

Extending radiation to the lymph nodes behind the sternal wall and above the collarbone extends overall survival in patients with stage I to III breast cancer and does not increase toxicity compared to conventional locoregional radiation therapy, according to 10-year results of an international...

breast cancer

FDA Approves Neoadjuvant Pertuzumab for Early-Stage Breast Cancer

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel for patients with early-stage breast cancer in the neoadjuvant setting. Pertuzumab is the first FDA-approved drug for the neoadjuvant...

solid tumors

ECC 2013: Molecular Sequencing Identifies Drug Targets for Cancers of Unknown Primary Origin

Cancers of unknown primary origin pose a treatment dilemma for oncologists and a great deal of anxiety for patients and their families. A study reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA39) shows that molecular profiling can identify targetable mutations in up to 80%...

skin cancer

ECC 2013: Multiple Studies Validate Long-Term Survival Benefit of Ipilimumab in Melanoma

There is no longer any doubt that for the treatment of metastatic or locally advanced melanoma, ipilimumab (Yervoy) conveys long-term survival benefits, according to studies presented at the European Cancer Congress 2013. In the largest survival analysis of the CTLA-4 monoclonal antibody to date...

prostate cancer

Telomere Length May Be a Prognostic Marker for Prostate Cancer

Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...

multiple myeloma

Addition of Vorinostat to Bortezomib Results in Small Progression-Free Survival Advantage in Previously-Treated Multiple Myeloma

In a phase III study (VANTAGE 088 trial) reported in The Lancet Oncology, Meletios Dimopolous, MD, of the University of Athens, and colleagues assessed the addition of the oral HDAC inhibitor vorinostat (Zolinza) to bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma. The...

lung cancer

Repurposed Antidepressants May Have Potential to Treat Small Cell Lung Cancer

A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small cell lung cancer, according to a study published in Cancer Discovery. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and ...

breast cancer

Intensity-Modulated Radiotherapy Associated With Superior Overall Cosmesis at 5 Years in Patients With Early Breast Cancer

Interim results of the Cambridge Breast Intensity-Modulated Radiotherapy trial indicated that intensity-modulated radiotherapy was associated with significantly reduced skin telangiectasia compared with standard radiotherapy at 2 years in patients with early breast cancer. The trial included a...

prostate cancer

Denosumab Increases Bone Metastasis-Free Survival According to PSA Doubling Time in Men With Nonmetastatic Castration-Resistant Prostate Cancer

In a recently reported phase III trial, denosumab (Xgeva) significantly increased bone metastasis–free survival and delayed time to first bone metastasis but did not improve overall survival compared with placebo in men with nonmetastatic castration-resistant prostate cancer and baseline...

ASTRO: Protecting Hippocampus During Whole-Brain Radiation Substantially Reduces Rate of Memory Loss in Cancer Patients

Protecting the stem cells that reside in and around the hippocampus substantially reduces the rate of cancer patients' memory loss during whole-brain radiotherapy without a significant risk of recurrence in that area of the brain, a new study shows. Results of the phase II clinical trial of...

lung cancer

Higher Post-Treatment FDG-PET Standardized Uptake Value Associated With Poorer Survival in Locally Advanced NSCLC

In a trial (ACRIN 6668/RTOG 0235 trial) reported in Journal of Clinical Oncology, Mitchell Machtay, MD, of Case Western Reserve University, and colleagues assessed the relationship between standardized uptake value for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and survival in...

skin cancer

Increases in Melanoma Incidence and Mortality Unremitting Over 6 Decades, Study Finds

In a study reported in Journal of Clinical Oncology, Alan C. Geller, MPH, RN, of the Harvard School of Public Health, and colleagues assessed long-term trends in the incidence and mortality of melanoma in Connecticut, a state with complete and consistent tumor registration. They found...

lymphoma

For Pregnant Women With Lymphoma, Standard Combination Chemotherapy Given After First Trimester Associated With Few Complications

Lymphoma is the fourth most frequent cancer to occur during pregnancy. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, of Tufts University Medical School, and colleagues examined treatment, complications, and outcomes for Hodgkin lymphoma...

Advertisement

Advertisement




Advertisement